Media.Player

Diabetes drug as a candidate for treatment of obesity and other metabolic diseases

Summary

Dipeptidyl peptidase 4 (DPP4) inhibitors are a commonly used treatment for type II diabetes mellitus. These FDA-approved drugs have been in wide use for over a decade, but have not been generally considered as a treatment for other metabolic disorders. Recent research suggests that DPP4 may play a wider role in metabolic diseases such as obesity and in related cardiovascular diseases such as atherosclerosis. This technology suggests DPP4 inhibitors for the treatment of inflammation implicated in a wider range of metabolic and related cardiovascular diseases. These inhibitors have potential as a drug therapy for patients who are obese, pre-diabetic, or otherwise suffering from metabolic disease.

Technology Benefits

Many DPP4 inhibitors are already FDA-approvedMay prevent the development of more costly and complex metabolic disorders in at-risk patientsPatent Information:Patent Pending (WO/2016/138132) Tech Ventures Reference: IR CU15173

Technology Application

Treatment of diseases caused by adipose tissue inflammationTreatment for pre-diabetic patients to slow the progress toward type II diabetesTreatment and prevention of obesityTreatment and prevention of metabolic diseases and related cardiovascular diseasesResearch tool for investigating adipose tissue inflammation in vivoResearch tool for investigating metabolic diseases

Detailed Technology Description

None

*Abstract

None

*Inquiry

Joan MartinezColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu

*IR

cu15173

*Principal Investigator

Country/Region

USA